Merck

November 14, 2018November 14, 2018

FDA Approves Keytruda for Liver Cancer Patients Who Had Received Nexavar

News

The U.S. Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab) as a treatment for patients with hepatocellular carcinoma (HCC) — the most common type of liver cancer — who previously ... Read more

November 13, 2018November 13, 2018

FDA Approves Keytruda-Chemotherapy Combo as First-line Therapy for NSCLC

News

Keytruda (pembrolizumab) can now be used in combination with chemotherapy — Paraplatin (carboplatin) plus Taxol (paclitaxel) or Abraxane (nab-paclitaxel) — as first-line therapy for patients with metastatic squamous non-small cell lung cancer ... Read more

November 9, 2018November 9, 2018

Keytruda Elicits Complete Response in 40% of Group of High-risk Bladder Cancer Patients, Early Phase 2 Trial Data Show

News

The immune checkpoint inhibitor Keytruda (pembrolizumab) completely eliminated tumors in almost 40% of a group of bladder cancer patients in an ongoing Phase 2 trial, Merck (known as MSD ... Read more

November 7, 2018November 7, 2018

CHMP Favors EU Approval of Keytruda for Advanced Melanoma Patients with Complete Tumor Resection

News

The Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency (EMA), has recommended the approval of Keytruda (pembrolizumab) for the treatment of advanced melanoma ... Read more

November 2, 2018November 2, 2018

Keytruda-Inlyta Combo Extends Survival in Advanced Renal Cell Carcinoma Patients, Phase 3 Trial Shows

News

A combination of Keytruda (pembrolizumab) and Inlyta (axitinib) significantly extended the lives of patients with advanced renal cell carcinoma (RCC) and delayed disease progression or death, according to a Phase 3 clinical ... Read more

October 24, 2018

Keytruda Improves Survival in Patients with Relapsed or Metastatic Head, Neck Cancer, Interim Data Show

News

First-line treatment with Keytruda (pembrolizumab) — alone or in combination with standard chemotherapy — significantly prolongs survival of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), ... Read more

October 16, 2018

1st Patient Dosed in Trial of IO102-Keytruda Combo in Treating Metastatic Lung Cancer

News

IO Biotech has dosed the first patient in a clinical trial testing the safety and efficacy of IO102 in combination with Merck’s Keytruda (pembrolizumab) as a first-line treatment for patients with metastatic ... Read more

September 25, 2018September 25, 2018

FDA Grants Priority Review to Keytruda as First-line Therapy for Advanced NSCLC

News

The U.S. Food and Drug Administration (FDA) has agreed to review Merck‘s application seeking the extension of Keytruda (pembrolizumab) as first-line treatment for patients with advanced non-small cell lung cancer (NSCLC). ... Read more

September 21, 2018

Keytruda Granted Priority Review by FDA for Treatment of Merkel Cell Carcinoma

News

The U.S. Food and Drug Administration granted priority review to Merck’s supplemental Biologics License Application seeking accelerated approval for Keytruda (pembrolizumab) as a treatment for adults and children with recurrent ... Read more

September 14, 2018September 14, 2018

Keytruda and Chemotherapy Combo Now 1st-Line Treatment for Advanced NSCLC in EU

News

The European Commission approved the use of Keytruda (pembrolizumab), in combination with Alimta (pemetrexed) and platinum-based chemotherapy, as a first-line treatment for metastatic nonsquamous non-small cell lung cancer (NSCLC). The approval is ... Read more

Pin It on Pinterest